Complement activation by antibodies bound to pathogens, tumors, and self antigens is a critical feature of natural immune defense, a number of disease processes, and immunotherapies. How antibodies activate the complement cascade, however, is poorly understood. We found that specific noncovalent interactions between Fc segments of immunoglobulin G (IgG) antibodies resulted in the formation of ordered antibody hexamers after antigen binding on cells. These hexamers recruited and activated C1, the first component of complement, thereby triggering the complement cascade. The interactions between neighboring Fc segments could be manipulated to block, reconstitute, and enhance complement activation and killing of target cells, using all four human IgG subclasses. We offer a general model for understanding antibody-mediated complement activation and the design of antibody therapeutics with enhanced efficacy.
C omplement activation by antibodies initiates immune protection through the generation of an array of biologically active products including opsonins, anaphylatoxins, chemotactic agents, and membrane attack complexes (1, 2) . The classical pathway of complement is triggered when antigen-bound immunoglobulin M (IgM) or IgG antibody molecules bind C1, which consists of the multimeric pattern recognition molecule C1q and a heterotetramer of the proteases C1r and C1s (3, 4) . C1q binds a single IgG Fc segment with very low affinity (dissociation constant K d ≈ 10 −4 M) (5, 6) , and physiological C1 binding thus requires an increase in the apparent binding constant-for instance, through antigen-driven antibody clustering, which allows multivalent C1q binding (7) . The molecular events governing complement activation, including the C1-antibody stoichiometry required for optimal activation, remain poorly understood (3, (8) (9) (10) (11) (12) (13) . Here, we set out to characterize and visualize the first steps in complement activation by IgG at the molecular level.
In the structure of human anti-HIV-1 gp120 antibody IgG1-b12 at 2.7 Å resolution [Protein Data Bank (PDB) entry 1HZH] (14, 15) , the IgG Fc segments are arranged in a hexameric ring (Fig. 1A) . A similar crystal packing is found for human antibody 2G12 (16) . The spatial orientation of Lys 322 (Fig. 1A) , a critical residue in the C1q binding site on IgG, suggested a compatibility of the hexamer with the arrangement of the six antibody-binding headpieces in C1q. We hypothesized that IgG antibodies activate complement-dependent cytotoxicity (CDC) via ordered clustering into hexamers through specific noncovalent Fc interactions. To investigate this hypothesis, we used a peptide that has been shown to bind residues in the observed Fc-Fc interface (17) (Fig. 1B) . The peptide inhibited CDC of human B cell lymphomas by CD20 antibody IgG1-7D8 and CD38 antibody IgG1-005 (Fig. 1C) , both of which potently induce CDC by the classical pathway (18, 19) . Next, we generated interface mutations designed to weaken Fc-Fc interactions. We confirmed that antigen binding and C1q binding to randomly immobilized IgG1 (fig. S1) were mostly unaffected by the mutations. In contrast, the apparent avidity of C1q for cell-bound IgG1-7D8 mutated at positions Ile   253   , His   433   , or Asn   434 decreased by as much as a factor of 20 (Fig. 1D,  fig. S2A , and table S1); this resulted in reduced complement activation and CDC, consistent with other mutations in the Fc-Fc interface (Fig. 1E, fig.   S2A , and (Fig. 1, F and G, and tables S1 and S2).
We also identified mutations that resulted in significantly enhanced CDC, as exemplified by E345R (Glu 345 → Arg), which increased C1q avidity to opsonized cells by a factor of~5 and CDC by a factor of~10 when introduced into CD20 antibody IgG1-7D8 ( Fig. 2A and tables S1 and S2) (20) . Similarly, the E345R substitution increased CDC of CD38 antibody IgG1-005 (Fig. 2B ) as well as of its IgG2, IgG3, and IgG4 isotype variants (Fig. 2C) (Fig. 3B) , and negative-stain electron tomography (ET) (Fig. 3, C to F) . Solution-phase hexamers of IgG1-005-RGY directly activated complement when added to human serum, as shown by the generation of C4d (Fig. 2D) . This was also observed for IgG1-7D8-RGY, a triple mutant of the CD20 antibody. Together, these findings directly link a biophysically characterized noncovalent IgG1 hexamer with classical pathway complement activation. Finally, IgG1-005-RGY showed a further potency increase when bound to cells, as shown by stronger CDC at low concentrations relative to the single mutant ( Fig. 2E ), which may be explained by preformed hexamers or enhanced Fc-Fc-mediated assembly on the cell surface.
To image C1 binding to antigen-bound IgG on a membrane, we performed cryo-electron tomography (cryo-ET) using dinitrophenyl (DNP)-labeled liposomes (20) . In the cryo-ET reconstructions, antibodies on the liposome surface assembled in single-layer patches with maximum density at a distance of 11 nm from the membrane (fig. S3, A and E) (20) . Addition of purified C1 protein, C4-depleted serum, or normal human serum resulted in C1 binding on top of the antibody layer (fig. S3, F to H). Cryo-ET tomograms of 107 particles representing antibody-C1 complexes were averaged ( fig. S4 ), resulting in an electron density map at low (>6 nm) resolution. The map showed a lower platform at 11 nm (coinciding with the maximum density observed on liposomes with antibody alone), a second platform at 20 nm, and a stalk on top of the upper platform (Fig. 4A) . Horizontal sections through the tomogram average indicated that the lower platform was composed of a continuous disk with six poorly resolved densities protruding toward the membrane and four discernible densities on top, arranged as an incomplete hexagon (Fig. 4 , B to E). We generated a model of the C1-antibody complex by docking the 1HZH crystal packing [adapted by Fab rotation ( fig. S5) ] into the lower platform and manually fitting C1q headpieces ( Fig. 4F and fig. S6 ) (20) . The four densities on top of the lower platform suggested incomplete (4:6) C1q headpiece binding to the antibody hexamer (Fig. 4C ) and may reflect flexibility and dynamics of the C1q-IgG interactions.
The model suggested that one Fab arm of each antibody in the hexamer bound the membraneassociated antigen while the other Fab arm was positioned at the height of the platform (Fig. 4F) . To test the concept that complement activation might only require monovalent binding, we generated functionally monovalent bispecific antibodies (20, 21) that contained one specific and one innocuous Fab arm (i.e., IgG1-7D8/b12 and IgG1-2F8/b12, monovalently binding CD20 and EGFR, respectively). Both antibodies induced efficient CDC of relevant target cells (Fig. 4 , G and H), which for the bispecific antibody 2F8/b12 was strongly enhanced relative to the parental 2F8 antibody. Thus, for this antibodyantigen pair, monovalent binding is better able than (high-affinity) bivalent binding to accommodate the Fc-Fc hexamerization required for efficient CDC.
The hexameric IgG-C1 binding model (Fig. 4,  A and F, and fig. S6) (12, 19, 22) , presumably because antigen size, density, and fluidity may affect activation (18, (22) (23) (24) (25) (26) and because IgG orientation resulting from epitope geometry imposes additional structural constraints (12, 19, 22, 25, 27) . Polyclonal antibodies appear to be less sensitive than monoclonal antibodies to such constraints (24, 28, 29) is nonetheless compatible with observations that smaller IgG complexes may suffice to initiate some complement activation (8, 32) . However, low-avidity C1q binding will result in only modest complement activity (27) , whereas the IgG hexamer will bind C1q most avidly, thus ensuring optimal complement activation when required. The observation that IgG hexamerization after antigen binding leads to effective complement activation could be exploited by increasing Fc-Fc contact formation. Because the E345R mutation bestowed complement-activating capability on all human IgG subclasses, IgG hexamerization may be a general concept applicable to the engineering of therapeutic antibodies with enhanced activity. 
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